ILC 2023 Posters

The poster PDFs provided here have been shared with the consent of the authors. This collection includes poster PDFs for 29 out of 50 posters, depending on which authors granted permission for their poster PDFs to be published.

Poster Number	PrimaryAuthor	Title	Category
1	Gitte Zels	Overview of patients with invasive lobular breast carcinoma included in the post-mortem tissue donation program, UPTIDER	Clinical Characteristics
2	Qian Zhao	Clinical Characteristics and Outcomes of Invasive Lobular Carcinoma	Clinical Characteristics
3	Jasmine Timbres	Risk factors pre-disposing to LCIS and ILC	Clinical Characteristics
4	Josephine Van Cauwenberge	Reporting on invasive lobular carcinoma in clinical drug trials and trials investigating gene expression profiles and molecular screening programs – a systematic review	Clinical Characteristics
5	Siobhan Freeney	Enhancing Knowledge and Research in Europe for Invasive Lobular Breast Cancer: Unique Challenges across European Countries	Clinical Characteristics
6	Helen Coulthard	“they… kept saying there’s nothing there”: British Women’s accounts of delayed lobular breast cancer diagnosis	Diagnosis
7	Laurie Hutcheson	Individuals with Invasive Lobular Carcinoma (ILC) Raise their Voices about ILC and Surgery	Diagnosis
8	Luca Nicosia	Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the management of breast lobular neoplasia: a new scenario in facing the diagnosis of an insidious disease	Diagnosis
10	Annapurna Gupta	Downregulation of Arginosuccinate synthase 1 confers Tamoxifen Resistance in Invasive Lobular Breast Cancer	Treatment Strategies
11	Bernadette Heemskerk-Gerritsen	The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in Invasive Lobular Breast Cancer Patients treated with endocrine therapy: a retrospective cohort study	Treatment Strategies
13	Christina Gersch	Characterization of Resistance to CDK4/6 Inhibitors and Endocrine Therapy in Invasive Lobular Breast Cancers Cell Lines	Treatment Strategies
16	Melinda Sanders	High prevalence of HER2-low among ILC with residual disease following neoadjuvant therapy provides therapeutic opportunities with HER2-antibody-drug conjugates	Treatment Strategies
17	William Yang	E-cadherin loss imparts mitotic vulnerabilities rendering breast cancer cells synthetic lethal to crizotinib and up-regulation of Src signalling reverses this effect	Treatment Strategies
20	Francesca Magnoni	Comparison of long-term outcome between high risk lobular versus ductal breast cancer: a propensity score matched study	Prognosis
21	Rebecca Riggins	Glutamate metabolic enzymes associate with increased tumor size in black women with invasive lobular breast cancer: a single-institution study	Prognosis
22	Simran Sandhu	Racial Disparities in Survival in Lobular Breast Cancer	Prognosis
23	Baylee Porter	Glucocorticoid receptor activation inhibits tumor cell growth while increasing metastatic characteristics in models of invasive lobular breast cancer	Metastasis
24	Bernadette Heemskerk-Gerritsen	Localization of metastatic disease in patients with a history of lobular carcinoma of the breast	Metastasis
27	Andi Cani	Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance	Biomarker
28	Chinasa A Ufondu	Assessing the Effect of E-cadherin loss on Estrogen Receptor activity in Human Mammary Epithelial Cell Models	Biomarker
30	Luyu Jia	Mutating E-cadherin in Rats to Model Lobular Breast Cancer	Biomarker
31	Madeleine Shackleford	WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in invasive lobular carcinoma cells	Biomarker
32	Maggie Musick	E-cadherin suppression supports transcriptional programs of lineage plasticity in early ILC tumorigenesis	Biomarker
36	Matteo Serra	Spatially resolved analysis of tumor microenvironment revealed biologically driven subgroups with distinct clinical outcome in invasive lobular carcinoma	TME
37	Emmanuelle mouret-fourme	Clinical Characteristics of Lobular Breast Carcinoma in CDH1 genetic predisposition. Experience from the Institut Curie	Genetics
40	Rita Canas-Marques	Aberrant E-cadherin (E-cad) Expression in Lobular Carcinoma in Situ (LCIS): A Comprehensive Evaluation of N-terminal, Extracellular, and C-terminal E-cadherin Domains	Genetics
41	Jing Yu	Lobular-like invasive mammary carcinoma: Is this a ductal cancer, lobular cancer, or a distinct entity?	Genetics
44	Sanghoon Lee	Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas	Epigenomics
48	Sarah Nash	Transcriptomic and immune heterogeneity underpin the biology of pleomorphic invasive lobular breast cancer	Multiomics